Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy

Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249

CAS  PubMed  Article  Google Scholar 

Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184:5309–5337

CAS  PubMed  Article  Google Scholar 

Sharma P, Allison JP (2020) Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 20:75–76

CAS  PubMed  Article  Google Scholar 

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707–723

CAS  PubMed  PubMed Central  Google Scholar 

Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069–1086

PubMed  Article  Google Scholar 

Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74

CAS  PubMed  Article  Google Scholar 

Snahnicanova Z, Kasubova I, Kalman M, Grendar M, Mikolajcik P, Gabonova E, Laca L, Caprnda M, Rodrigo L, Ciccocioppo R, Kruzliak P, Plank L, Lasabova Z (2020) Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer. Clin Exp Med 20:87–95

CAS  PubMed  Article  Google Scholar 

Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P (2016) Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397-404 e9

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L (2016) Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44:1255–1269

CAS  PubMed  Article  Google Scholar 

Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208–220

CAS  PubMed  PubMed Central  Article  Google Scholar 

De Sanctis F, Bronte V, Ugel S (2016) Tumor-induced myeloid-derived suppressor cells. Microbiol Spectr 4(3). https://doi.org/10.1128/microbiolspec.MCHD-0016-2015

Trovato R, Cane S, Petrova V, Sartoris S, Ugel S, De Sanctis F (2020) The engagement between MDSCs and metastases: partners in crime. Front Oncol 10:165

PubMed  PubMed Central  Article  Google Scholar 

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268

CAS  PubMed  PubMed Central  Article  Google Scholar 

Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19:108–119

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31–46

CAS  PubMed  Article  Google Scholar 

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541–550

CAS  PubMed  PubMed Central  Article  Google Scholar 

Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. Science 327:656–661

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sica A, Guarneri V, Gennari A (2019) Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. Cell Stress 3:284–294

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ugel S, Cane S, De Sanctis F, Bronte V (2021) Monocytes in the tumor microenvironment. Annu Rev Pathol 16:93–122

CAS  PubMed  Article  Google Scholar 

Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B (2022) Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell 40:674–93 e7

CAS  PubMed  Article  Google Scholar 

Ugel S, De Sanctis F, Mandruzzato S, Bronte V (2015) Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125:3365–3376

PubMed  PubMed Central  Article  Google Scholar 

Hegde S, Leader AM, Merad M (2021) MDSC: Markers, development, states, and unaddressed complexity. Immunity 54:875–884

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20:7–24

CAS  PubMed  Article  Google Scholar 

Engblom C, Pfirschke C, Pittet MJ (2016) The role of myeloid cells in cancer therapies. Nat Rev Cancer 16:447–462

CAS  PubMed  Article  Google Scholar 

Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431–446

CAS  PubMed  Article  Google Scholar 

Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P (2019) Neutrophil diversity in health and disease. Trends Immunol 40:565–583

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mantovani A, Marchesi F, Jaillon S, Garlanda C, Allavena P (2021) Tumor-associated myeloid cells: diversity and therapeutic targeting. Cell Mol Immunol 18:566–578

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231–237

CAS  PubMed  Article  Google Scholar 

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14–20

CAS  PubMed  PubMed Central  Article  Google Scholar 

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964

CAS  PubMed  Article  Google Scholar 

Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F (2016) Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 65:1710–1720

PubMed  Article  Google Scholar 

Marigo I, Trovato R, Hofer F, Ingangi V, Desantis G, Leone K, De Sanctis F, Ugel S, Cane S, Simonelli A, Lamolinara A, Iezzi M, Fassan M, Rugge M, Boschi F, Borile G, Eisenhaure T, Sarkizova S, Lieb D, Hacohen N, Azzolin L, Piccolo S, Lawlor R, Scarpa A, Carbognin L, Bria E, Bicciato S, Murray PJ, Bronte V (2020) Disabled homolog 2 controls prometastatic activity of tumor-associated macrophages. Cancer Discov 10:1758–1773

CAS  PubMed  Article  Google Scholar 

DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369–382

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cassetta L, Pollard JW (2018) Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 17:887–904

CAS 

留言 (0)

沒有登入
gif